Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.56 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9185883 | 0.90 | KMT2A (0.56) | KCNMA1GPR35MEN1KMT2APOLB | |
| SCHEMBL7253753 | 0.85 | KCNMA1 (0.57) | KCNMA1GPR35MEN1KMT2APOLB | |
| SCHEMBL7253758 | 0.85 | KCNMA1 (0.57) | KCNMA1GPR35MEN1KMT2APOLB | |
| SCHEMBL30388557 | 0.83 | KCNMA1 (0.63) | KCNMA1MEN1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL5144247 | 0.83 | KCNMA1 (0.63) | KCNMA1MEN1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL5335266 | 0.83 | KCNMA1 (0.52) | KCNMA1GPR35MEN1KMT2APOLB | |
| SCHEMBL9872830 | 0.82 | MEN1 (0.50) | KCNMA1GPR35MEN1KMT2APOLB | |
| SCHEMBL30625900 | 0.82 | KMT2A (0.50) | KCNMA1GPR35MEN1KMT2APOLB | |
| SCHEMBL505372 | 0.82 | KCNMA1 (0.51) | KCNMA1MEN1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL3412286 | 0.82 | MEN1 (0.50) | KCNMA1GPR35MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339663-B1 | NAPHTHALENE DERIVATIVES | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2338886-A2 | Naphthalene derivatives | Novartis AG (CH) | 2011-06-29 | — | — | EP | disclosed |
| US-20100035871-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | WYETH | 2010-02-11 | — | — | US | disclosed |
| US-7045533-B2 | Such as naphthalen-1-yl-(4-pentyloxy-naphthalen-1-yl)-mehtane for treatment/prevention of diseases/conditions associated with cannobinoid receptor activation such as chronic pain, osteo- and rheumatoid arthritis, teno-synovitis and gout | NOVARTIS AG (CH) | 2006-05-16 | — | — | US | disclosed |
| CN-1224598-C | Naphthalene derivatives | NOVARTIS AG (CH) | 2005-10-26 | — | — | CN | disclosed |
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
| US-20040053890-A1 | Naphthalene derivatives | NOVARTIS AG (CH) | 2004-03-18 | — | — | US | disclosed |
| CN-1476424-A | Naphthalene derivatives | ��˹��ŵ�� | 2004-02-18 | — | — | CN | disclosed |
| EP-1339663-A2 | NAPHTHALENE DERIVATIVES | Novartis AG (CH) | 2003-09-03 | — | — | EP | disclosed |
| US-5071468-A | Cereal selectivity | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 1991-12-10 | — | — | US | disclosed |
| EP-0375076-A1 | Heterocyclic herbicides | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1990-06-27 | — | — | EP | disclosed |
| US-4417896-A | NITRO-,AMINO-,PHENOXYALKANOLS | SOCIETE ANONYME DITE: L'OREAL (FR) | 1983-11-29 | — | — | US | disclosed |
| EP-0011843-B1 | DEVELOPING COMPONENTS FOR HAIR OXYDATION DYES, THEIR PREPARATION AND HAIR DYES CONTAINING THEM | Henkel Kommanditgesellschaft auf Aktien (DE) | 1982-09-15 | — | — | EP | disclosed |
| US-4337061-A | NITRO DYES IN AQUEOUS SOLUTION | SOCIETE ANONYME DITE: L'OREAL (FR) | 1982-06-29 | — | — | US | disclosed |
| EP-0011844-B1 | COUPLING COMPONENTS FOR OXIDIZING HAIR DYES, THEIR PREPARATION AND HAIR DYES CONTAINING THEM | Henkel Kommanditgesellschaft auf Aktien (DE) | 1982-05-26 | — | — | EP | disclosed |
| US-4231964-A | Nitroamines, processes for their manufacture and their use as diazo components | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-11-04 | — | — | US | disclosed |
| EP-0011844-A1 | Coupling components for oxidizing hair dyes, their preparation and hair dyes containing them | Henkel Kommanditgesellschaft auf Aktien (DE) | 1980-06-11 | — | — | EP | disclosed |
| EP-0011843-A2 | Developing components for hair oxydation dyes, their preparation and hair dyes containing them | Henkel Kommanditgesellschaft auf Aktien (DE) | 1980-06-11 | — | — | EP | disclosed |
| US-4169091-A | Symmetrical and asymmetrical disazo compounds containing a bis-(nitro-aryloxy)alkane middle component | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053890-A1 | Naphthalene derivatives | CYP1A1, SULT1E1, CYP2F1 | KCNMA1 1761/4885GPR35 2663/4885MEN1 760/4885 |
| US-20100035871-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | HTR2C, HTR5A, NPY1R | KCNMA1 1087/4885GPR35 145/4885MEN1 4176/4885 |
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | KCNMA1 1697/4885GPR35 2860/4885MEN1 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.